NCT04252495View on ClinicalTrials.gov

The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 26, 2020

Primary Completion Date

April 5, 2021

Study Completion Date

May 6, 2021

Conditions
Hepatic ImpairmentHealthy Subjects
Interventions
DRUG

Aprocitentan

A single oral dose of 25 mg.

Trial Locations (2)

24105

CRS Clinical Research Services Kiel GmbH, Kiel

05-410

Biokinetica S.A., Józefów

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY